Compare SPXC & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPXC | GRFS |
|---|---|---|
| Founded | 1912 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 4.9B |
| IPO Year | 1994 | 2008 |
| Metric | SPXC | GRFS |
|---|---|---|
| Price | $168.75 | $7.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $270.67 | $10.87 |
| AVG Volume (30 Days) | ★ 462.4K | 375.7K |
| Earning Date | 10-29-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.17% |
| EPS Growth | ★ 18.08 | N/A |
| EPS | ★ 2.73 | N/A |
| Revenue | ★ $2,265,100,000.00 | N/A |
| Revenue This Year | $21.39 | $1.73 |
| Revenue Next Year | $12.13 | $6.26 |
| P/E Ratio | $63.55 | ★ $18.67 |
| Revenue Growth | ★ 14.17 | N/A |
| 52 Week Low | $169.19 | $6.96 |
| 52 Week High | $251.08 | $10.16 |
| Indicator | SPXC | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 26.15 | 41.48 |
| Support Level | N/A | $7.21 |
| Resistance Level | $225.50 | $8.41 |
| Average True Range (ATR) | 5.74 | 0.10 |
| MACD | -0.32 | -0.00 |
| Stochastic Oscillator | 0.91 | 36.67 |
SPX Technologies Inc supplies engineered heating, ventilation, and air conditioning, or HVAC, products, as well as detection and measurement technologies and power equipment. The company operates through two reportable segments. The HVAC segment which generates the majority of the revenue for the company, designs, manufactures, installs, and services cooling products, as well as heating and ventilation products. The Detection and Measurement technologies segment designs, manufactures, and installs underground pipe and cable locators and inspection equipment, bus-fare collection systems, and others. Geographically, the company has its operations in the United States, Canada, China, the United Kingdom, and Others. It derives maximum revenue from United States.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.